Linked Life Data

20146223

Source:http://linkedlifedata.com/resource/pubmed/id/20146223

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2010-2-17
pubmed:abstractText
We summarize data presented on the use of high-dose chemotherapy (HDCT) with stem cell rescue for patients with recurrent medulloblastoma and other primitive neuroectodermal tumors as presented at an international consensus and state of the art workshop held in Milan in 2006. Eight, mainly institutional, studies were presented that included 159 patients who received HDCT of whom 22% were disease-free survivors at the time of reporting. Of those receiving HDCT and who relapsed having received previous radiotherapy, 17.3% were disease-free survivors at the time of reporting. However, from the two national studies that reported results from the time of relapse, only 4.2% were event free survivors. The outlook for previously irradiated patients with recurrent PNETs remains extremely poor and more effective therapeutic approaches are needed.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
1545-5017
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
54
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
649-51
pubmed:meshHeading
pubmed:year
2010
pubmed:articleTitle
Role of high-dose chemotherapy for recurrent medulloblastoma and other CNS primitive neuroectodermal tumors.
pubmed:affiliation
St Jude Children's Research Hospital, Memphis, Tennessee, USA.
pubmed:publicationType
Journal Article, Review